These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28453754)

  • 1. Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial.
    Turner D; Yerushalmi B; Kori M; Broide E; Mozer-Glassberg Y; Shaoul R; Kolho KL; Shteyer E; Shamaly H; Ledder O; Cohen S; Peleg S; On A; Levine A
    J Crohns Colitis; 2017 May; 11(5):527-533. PubMed ID: 28453754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of once daily versus twice daily mesalazine for mild-to-moderate ulcerative colitis: A meta-analysis of randomized controlled trials.
    Zheng X; Zhang Z; Wang B; Li J; Qiu C; Zhang Q; Wang X
    Medicine (Baltimore); 2019 Apr; 98(14):e15113. PubMed ID: 30946380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.
    Kruis W; Kiudelis G; Rácz I; Gorelov IA; Pokrotnieks J; Horynski M; Batovsky M; Kykal J; Boehm S; Greinwald R; Mueller R;
    Gut; 2009 Feb; 58(2):233-40. PubMed ID: 18832520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
    Flourié B; Hagège H; Tucat G; Maetz D; Hébuterne X; Kuyvenhoven JP; Tan TG; Pierik MJ; Masclee AA; Dewit O; Probert CS; Aoucheta D;
    Aliment Pharmacol Ther; 2013 Apr; 37(8):767-75. PubMed ID: 23451806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosing.
    Connolly MP; Kuyvenhoven JP; Postma MJ; Nielsen SK
    J Crohns Colitis; 2014 May; 8(5):357-62. PubMed ID: 24094599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study.
    Hyams JS; Davis S; Mack DR; Boyle B; Griffiths AM; LeLeiko NS; Sauer CG; Keljo DJ; Markowitz J; Baker SS; Rosh J; Baldassano RN; Patel A; Pfefferkorn M; Otley A; Heyman M; Noe J; Oliva-Hemker M; Rufo P; Strople J; Ziring D; Guthery SL; Sudel B; Benkov K; Wali P; Moulton D; Evans J; Kappelman MD; Marquis A; Sylvester FA; Collins MH; Venkateswaran S; Dubinsky M; Tangpricha V; Spada KL; Britt A; Saul B; Gotman N; Wang J; Serrano J; Kugathasan S; Walters T; Denson LA
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):855-868. PubMed ID: 28939374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.
    Kamm MA; Lichtenstein GR; Sandborn WJ; Schreiber S; Lees K; Barrett K; Joseph R
    Gut; 2008 Jul; 57(7):893-902. PubMed ID: 18272546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000544. PubMed ID: 23076890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.
    Gross V; Bunganic I; Belousova EA; Mikhailova TL; Kupcinskas L; Kiudelis G; Tulassay Z; Gabalec L; Dorofeyev AE; Derova J; Dilger K; Greinwald R; Mueller R;
    J Crohns Colitis; 2011 Apr; 5(2):129-38. PubMed ID: 21453882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Murray A; Nguyen TM; Parker CE; Feagan BG; MacDonald JK
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD000543. PubMed ID: 32786164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing.
    Bokemeyer B; Hommes D; Gill I; Broberg P; Dignass A
    J Crohns Colitis; 2012 May; 6(4):476-82. PubMed ID: 22398060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesalamine Enemas for Induction of Remission in Oral Mesalamine-refractory Pediatric Ulcerative Colitis: A Prospective Cohort Study.
    Levine A; Yerushalmi B; Kori M; Broide E; Mozer-Glassberg Y; Shaoul R; Kolho KL; Shteyer E; Shamaly H; Ledder O; Cohen S; Peleg S; Shabat CS; Focht G; Shachmon E; Boaz M; On A; Turner D
    J Crohns Colitis; 2017 Aug; 11(8):970-974. PubMed ID: 28369299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once daily vs multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis.
    Li W; Zhang ZM; Jiang XL
    Colorectal Dis; 2016 Jul; 18(7):O214-23. PubMed ID: 27214762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis.
    D'Haens GR; Sandborn WJ; Zou G; Stitt LW; Rutgeerts PJ; Gilgen D; Jairath V; Hindryckx P; Shackelton LM; Vandervoort MK; Parker CE; Muller C; Pai RK; Levchenko O; Marakhouski Y; Horynski M; Mikhailova E; Kharchenko N; Pimanov S; Feagan BG
    Aliment Pharmacol Ther; 2017 Aug; 46(3):292-302. PubMed ID: 28568974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
    Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
    Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis.
    Hawthorne AB; Stenson R; Gillespie D; Swarbrick ET; Dhar A; Kapur KC; Hood K; Probert CS
    Inflamm Bowel Dis; 2012 Oct; 18(10):1885-93. PubMed ID: 22081522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probiotics for induction of remission in ulcerative colitis.
    Kaur L; Gordon M; Baines PA; Iheozor-Ejiofor Z; Sinopoulou V; Akobeng AK
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD005573. PubMed ID: 32128795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
    Sandborn WJ; Korzenik J; Lashner B; Leighton JA; Mahadevan U; Marion JF; Safdi M; Sninsky CA; Patel RM; Friedenberg KA; Dunnmon P; Ramsey D; Kane S
    Gastroenterology; 2010 Apr; 138(4):1286-96, 1296.e1-3. PubMed ID: 20064514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.